Efficacy and safety of carbon ion radiotherapy in 16 fractionations for prostate cancer

Efficacy and safety of carbon ion radiotherapy in 16 fractionations for prostate cancer - carbon ion radiotherapy for prostate cancer (16 fractionations)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003827

Enrollment

130

Registered

2010-06-25

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed prostate cancer (adenocarcinoma) 2) Gleason score was confirmed 3) T1cN0M0 (UICC 6th, 2002) 4) PSA before biopsy was confirmed 5) Age 20-80 6) PS 0-2 7) informed concent was given

Exclusion criteria

Exclusion criteria: 1) History of pelvic irradiation 2) History of TUR-Bt or HIFU 3) HIstory of chemotherapy 4 weeks before treatment 4) life expectancy less than 6 months 5) Active double cancer 6) neoadjuvant hormonal therapy more than 8 months 7) hormone-refractory prostate cancer 8) difficulty with planned hormonal therapy 9) Corticosteroid or antiandrogen therapy for concomitant disease 10) severe comcomitant disease 11) other medically or psychologically unsuitable reasons

Design outcomes

Primary

Measure	Time frame
Biochemocal relapse-free rate at 5 years	—

Countries

Japan

Contacts

Public ContactTatsuya Ohno

Gunma University Gunma University Heavy Ion Medical Center

tohno@gunma-u.ac.jp027-220-8378

Outcome results